[Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].
88 patients with benign prostatic hyperplasia (BPH) were given the inhibitor of 5 alpha-reductase proscar (finasteride, Merck and Co. Inc., USA) for 12-14 months and uroselective blocker of alpha-adrenoreceptors alfuzosin (dalfas, Synthelabo Group, France) for 4-5 months. The patients were examined before the combined treatment and on the treatment month 1, 3, 6 and 12. The proscar plus alfuzosin combination produced a response after 2-3-week treatment due to alpha-blocker Further, the effect was enhanced by the action of inhibitor of 5 alpha-reductase. Combination of alfuzosin with proscar meets three principal requirements demanded of BPH chemotherapy: improves urination, inhibits the growth of adenomatous tissue, diminishes the size of the enlarged prostate.
Tkachuk
V N
VN
Al'-Shukri
S Kh
SKh
Luk'ianov
A E
AE
Kornienko
V I
VI
Kuz'min
I V
IV
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D042944:Cholestenone 5 alpha-Reductase; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage*; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D018120:Finasteride; C047638:alfuzosin; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase
Kombinirovannoe primenenie ingibitorov 5al'fa-reduktazy i blokatorov al'fa1-adrenoretseptorov u bol'nykh dobrokachestvennoĭ giperplazieĭ prostaty.